Promising results for HPV+ cancers have also been obtained: we recently demonstrated that two JAK inhibitors, ruxolitinib and fedratinib, reduced STAT3 and STAT5 phosphorylation, decreased proliferation and induced apoptosis in HPV+ cervical cancer cells [163]. This evidence concerns the gene STAT3 and cervical cancer.